Trinomab Completes Nearly RMB 700 Million Series A+ Financing to Advance Global Development of Its Pipeline of Naturally Derived Fully Human Monoclonal Antibody Therapeutics

VCBeat learned at the earliest opportunity,Zhuhai Trinomab Biotechnology Co., Ltd. (hereinafter referred to as “Trinomab”) announced the completion of its Series A+ financing round, raising nearly RMB 700 million.This round of financing was jointly completed by CMB International, Shangxin Capital, CICC Capital Qide Fund, Sunshine Ronghui, Guozhong Capital, Superstring Capital, and Tianhui Capital.

The proceeds from this round of financing will be used to further industrialize the company’s pipeline of novel natural fully human antibody drugs.Specifically including:

1) International Multicenter Clinical Trial of the Fully Human Anti-Tetanus Toxin Monoclonal Antibody Drug [TNM002];

2) International Multicenter Clinical Trial of the Fully Human Anti-Respiratory Syncytial Virus Monoclonal Antibody Drug [TNM001];

3) IND applications in China and the US, and subsequent clinical studies, for multiple fully human antibody new drug candidates in the preclinical stage;

4) Construction of Phase II facilities for the fully human antibody drug production base, etc.

Trinomab, founded in 2015, is a global, clinical-stage innovative biopharmaceutical company dedicated to the research and development ofOriginal Fully Human Monoclonal Antibody Novel Drugas its core business. The company’s core technology is the fourth-generation antibody technology, “Integrated Technology Platform for Natural Fully Human Monoclonal Antibody Development (HitmAb)”^®)”. Since its inception, Trinomab has remained dedicated to developing novel, fully human monoclonal antibody drugs with independent intellectual property rights, high differentiation, and high efficacy, aiming to enhance the prevention and treatment outcomes for infectious diseases, autoimmune diseases, malignant tumors, and other conditions.

Antibody drugs developed through traditional technologies often face challenges related to anti-drug antibody (ADA) responses caused by immunogenicity, whereas novel natural fully human monoclonal antibodies can minimize or even avoid this issue.Trinomab's HitmAb^®Monoclonal antibodies isolated from the technical platform are natural, fully human monoclonal antibodies that have matured under the selective pressure of the human immune tolerance environment. This approach maximizes the avoidance of endogenous immunogenicity in antibody drugs, addresses the challenge of anti-drug antibody (ADA) responses in clinical applications, and thereby significantly reduces R&D and investment risks.

Furthermore, HitmAb^®The technology platform also effectively circumvents the time-consuming, labor-intensive, and lengthy processes associated with traditional antibody expression, such as cloning and vector construction. It enables “high-throughput,” “high-efficiency,” and “operability,” allowing for the isolation of target antibodies within as little as 7–10 days. Furthermore, this platform is open and scalable.

Figure 1. HitmAb: An Integrated Technology Platform for the Development of Natural Fully Human Monoclonal Antibodies^®Technical Roadmap

Currently, Trinomab’s multiple fully human monoclonal antibody new products are undergoing rapid commercialization, with some having entered clinical trial stages.Among these, the recombinant natural fully human monoclonal antibody against tetanus toxin, TNM002, initiated Phase I clinical trials in Australia in November 2020 and has recently received Investigational New Drug (IND) approvals from both China and the United States. The injection of TNM001, a recombinant fully human monoclonal antibody against respiratory syncytial virus, was approved for IND by the National Medical Products Administration (NMPA) this July and is expected to formally commence Phase I clinical trials in September this year. Additionally, the company’s natural fully human monoclonal antibodies against human cytomegalovirus (HCMV), nerve growth factor (NGF), and varicella-zoster virus (VZV) are scheduled to submit IND applications sequentially in 2022.

As Trinomab rapidly advances its product pipeline, the company continues to attract top talent to support its growth.Recently, Trinomab has consecutively appointed two industry veterans with extensive domestic and international clinical research experience as its Chief Medical Officer and Vice President of Clinical Development, respectively. Moving forward, Trinomab’s clinical team will continue to efficiently advance the clinical trials of its monoclonal antibody products, leveraging optimized clinical development strategies and risk control management to strategize the global rollout of its product portfolio.

“Trinomab has focused on applying its proprietary HitmAb technology since its establishment^®Technology Platform (Figure 1): Development of Novel Natural Fully Human Antibody Drugs. Initially aiming to replace animal- and human serum-derived products, we are developing novel monoclonal antibody drugs against infectious diseases that pose significant threats to infant and child health, as well as other antibody therapeutics addressing unmet clinical needs. In the future, we will continue to optimize HitmAb^®technical platform, we continue to enrich our product pipeline (Figure 2), advancing antibody candidates with strong druggability potential into clinical development and commercialization, thereby benefiting a broad patient population.”Dr. Liao Huaxin, Co-founder & Chairman & CTO of Trinomabindicates.

Figure 2. Trinomab’s Pipeline of Natural Fully Human Antibody Development Products

Regarding the successful completion of this round of financing,Trinomab Co-Founder, CEO & President Zheng WeihongMr. [Name] stated, “This round of financing has garnered the favor and recognition of numerous renowned investment institutions. Trinomab will further advance the commercialization of its product pipeline, extending the benefits of its products from China to patients worldwide, ranging from Singapore to the Central African Republic. We firmly believe that with the support of our many partners and the collective efforts of the Trinomab team, the company will achieve rapid and healthy growth, ultimately evolving into a globalized pharmaceutical enterprise.”

China Merchants Bank International (Hong Kong) Limited is a comprehensive, specialized financial services institution headquartered in Hong Kong, with deep roots in mainland China and a global outreach. As a wholly-owned subsidiary of China Merchants Bank, CMB International leverages the synergistic advantages of the Group’s domestic and overseas operations to actively implement a diversified business strategy, with comprehensive coverage across corporate finance, asset management, private equity, and other business segments. Jiangsu CMB Fund Management Co., Ltd. is a wholly-owned management company established by CMB International Capital in Jiangsu Province, with assets under management nearing RMB 20 billion. Its investment focus areas include biopharmaceuticals, next-generation information technology, advanced manufacturing, and new consumption sectors.

Shangxin Capital Management Co., Ltd. is a private equity fund management company primarily focused on equity investments in the healthcare and medical sectors. As of the end of 2020, its assets under management exceeded RMB 10 billion. In 2020, as a member of the Insurance Asset Management Association of China, the company received a Class A rating for private equity fund managers eligible to manage insurance fund investments.

CICC Qide (Xiamen) Innovative Biopharmaceutical Equity Investment Fund (hereinafter referred to as “CICC Capital Qide Fund”) is an equity investment fund under CICC Capital Operations Co., Ltd. (hereinafter referred to as “CICC Capital”) that focuses on innovative pharmaceuticals, representing a significant breakthrough in CICC Capital’s strategic layout within the biopharmaceutical industry.

Sunshine Ronghui is among the first private equity fund management companies in China’s insurance industry to be established with insurance capital. With assets under management reaching RMB 30 billion, it focuses on the healthcare and emerging technology sectors, investing in star enterprises such as Mindray, Ruipeng Pet Healthcare, InnoCare Pharma, Sinopharm (Shengnuo Pharmaceutical), Qichensheng, Chaoju Eye Care, Kuanteng Medical, Enflame Technology, InnoGrit Technology, and ESWIN.

Guozhong Capital won the bids to manage the “National Small and Medium-sized Enterprise Development Fund” twice, at the end of 2015 and the end of 2020, with a total assets under management of RMB 10 billion. It has become the only institution in China to consecutively win the bids for managing two physical funds under the National SME Development Fund, shouldering the important mission of promoting the development of the real economy and supporting small and medium-sized enterprises on behalf of the state.

Hyperstring Fund is a specialized healthcare investment firm headquartered in New York. Its management team boasts top-tier pharmaceutical R&D backgrounds in both China and the United States, along with extensive and in-depth industry expertise. The fund focuses on investing in biopharmaceutical, medical device, and healthcare service companies at various stages of development worldwide, providing rich industry perspectives and resources to support their long-term growth.

Tianhui Capital (i.e., Tianhui Hongyou & Tianhui Sumin Investment) is a value investor and navigator deeply rooted in the medical and healthcare industry. Its core team has 20 years of professional experience in investment management within the medical and healthcare sector, adopting a “four-pronged” investment strategy characterized by specialization, early-stage focus, platform-based development, and internationalization, with a focus on key areas such as precision medicine, high-end medical devices, innovative drugs, and novel therapeutic technologies.

Zhuhai R&D Center: 2nd Floor, No. 6C, Zhizao Avenue, Hongqi Town, Jinwan District, Zhuhai City

Zhuhai Production Base: Building 9, International Health Port, Sanzao Town, Jinwan District, Zhuhai City

Beijing Clinical Center: W2-911, Oriental Plaza, Dongcheng District, Beijing

U.S. Office: 4307 Forest Edge Trail, Durham, NC 27705, USA

Australian Office: 17 Bungowen Ave, Thornleigh, NSW Australia 2120

Tel: 0756-7263999

Email: trinomab@trinomab.com

1.World’s First Fully Human Monoclonal Antibody Against Tetanus Toxin Approved for Phase I Clinical Trials in Australia

2.Congratulations on Trinomab's TNM002 Monoclonal Antibody Receiving IND Approval from China's NMPA

3. Trinomab’s TNM002 Monoclonal Antibody Successfully Receives IND Approval from the U.S. FDA

4.Mr. Li Bin Officially Joins Trinomab as Vice President of Clinical Development

5. CMS Pharmaceutical Makes Equity Investment in Trinomab and Establishes a Joint Venture with the Company

6.Grand Ceremony Held for the Completion and Commissioning of Trinomab’s Digital Antibody Production Base!

7.Trinomab Announces Completion of RMB 450 Million Series A Financing

8. Trinomab’s TNM001 (RSV Monoclonal Antibody) Successfully Receives NMPA IND Approval

9. Dr. Wang Wanmei Joins Trinomab as Chief Medical Officer (CMO) and Senior Vice President (SVP)